Search
RG2417
go.drugbank.com/drugs/DB05055InvestigationalRecent reports indicate that certain genes that encode for mitochondrial proteins are significantly down regulated in the brains of bipolar patients. … RG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential
Human Retinoid X Receptors (RXRs)
go.drugbank.com/bio_entities/BE0010096TargetHumansReceptor for retinoic acid. … Receptor for retinoic acid.
Polypeptides: Retinoic acid receptor RXR-alpha, Retinoic acid receptor RXR-betaSynonyms: Retinoid X receptor alpha, Retinoid X receptor betaPeroxisome proliferator-activated receptors
go.drugbank.com/bio_entities/BE0010120TargetHumans and other mammalsReceptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. … Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids.
Polypeptides: Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor deltaSynonyms: Nuclear hormone receptor 1, Nuclear receptor subfamily 1 group C member 1Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalas the first approved drug for such use since 2014. … Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.
Vinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalLike other vinca agents, vinflunine is an anti-mitotic agent that induces a cell cycle arrest at the G2/M phase and promotes cell death via apoptosis [L1396]. … Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProstaglandin E2 Receptors
go.drugbank.com/bio_entities/BE0010100TargetHumansReceptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. … Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system.
Polypeptides: Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP2 subtypeSynonyms: PGE receptor EP1 subtype, Prostanoid EP1 receptorCamizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigationalCamizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally … [L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist.
Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor DegradersNalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalA narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. … Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalPertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Categories: HER2 Receptor Antagonists, Receptor, ErbB-2, antagonists & inhibitorsTemozolomide
go.drugbank.com/drugs/DB00853ApprovedInvestigational[L32033] Temozolomide was granted FDA approval on August 11, 1999, as an oral capsule and subsequently on February 27, 2009, as an intravenous injection. … [A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow
Categories: P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide